Victoria, British Columbia Thursday, November 14, 2024, 18:00 Hrs [IST] ...

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. <li /> Consistent improve ...

The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...

PDUFA date for potential approval of Zanidatamab is set for Nov 29, developed in collaboration with Jazz Pharmaceuticals and BeiGene. Find out why ZYME stock is a Buy.

as a treatment of the chronic disease eosinophilic esophagitis. Data describing the pharmacokinetic profile, safety and tolerability of the drug candidate was evaluated between every dose escalation.

Shares of Eupraxia Pharmaceuticals jumped after the company said it completed a private placement, selling 8.9 million of its Series 1 Preferred shares, each for 5 Canadian dollars ($3.59). The stock ...

The drug was generally safe and well tolerated up to 24 weeks of treatment, added Schoepfer, who presented the results during a presentation at the United European Gastroenterology (UEG ...

A version of the little blue pill – yes, that pill – could be key to helping harbor seals. According to SeaLife Response, ...

Background:Gastrointestinal (GI) cancer encompasses a group of malignancies affecting the digestive tract and related organs, including cancers of the colon, pancreas, stomach, liver, and esophagus.

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is set to showcase its innovative drug delivery solutions ...